Bill Alpert

Little did I realize a few grapes could send my blood sugar soaring until I tried the first glucose monitor without a prescription. I managed to lose seven pounds.

Semiconductor analyst William Stein says he finds himself in a strange situation. Chip stocks have done very well, the Truist Securities analyst writes in a Monday note. Demand for artificial intelligence products remains strong, but companies with diversified product lines have weak demand for many of their products.

The new Quest 3S headset starts at $300, as Facebook-parent Meta seeks to further undercut Apple’s new Vision Pro.

Government lawyers told a court yesterday that they were considering a Google breakup, among possible remedies for the Alphabet unit’s monopoly on internet search. Most of the 10-page text discussed restrictions on Google business practices that the government might seek, in its final remedy proposal to U.S. District Judge Amit Mehta in the District of Columbia’s federal court on Nov. 20. Judge Mehta concluded in August that Google monopolized search by paying phone makers and web browser developers to make Google their default search engine.

The watches, which can warn users of irregular heartbeats and sleep disturbances, are finding a modest number of new customers for makers of medical devices.

When a business is repeatedly slammed by Jamie Dimon, you know it’s a big deal. In his annual letter, the JPMorgan Chase boss tore into the private credit industry, warning that the business loans made by lightly regulated private funds will implode when the credit funds’ opaque valuations and illiquidity meet the economy’s next downturn. Private credit has been one of the fastest-growing businesses at alternative asset giants like Blackstone Apollo Global Management and Brookfield as well as specialists like Ares Management, Blue Owl Capital and HPS Investment Partners.

The transaction, seen as a vote of confidence, has put the focus on other drug firms testing similar barrier-bridging antibodies.

The company’s stock lost a third of its value Wednesday after the computer company disclosed that its auditor had resigned a week earlier.

Roche Holding has one of the most promising treatments for Alzheimer’s in clinical trials. Amid a Madrid conference for Alzheimer’s researchers, Roche scientists talked to investors about the company’s experimental diagnostics and drugs for the devastating brain disease—including trontinemab, the first anti-Alzheimer’s antibody that easily crosses the blood-brain barrier. Roche plans to start pivotal Phase 3 trials of the drug next year.

The data show that firing CEOs to revive stock prices has increased in the past few years, as more activists appear on the scene and the option of selling the company diminishes.